The invention provides a compound of formula (I), its stereoisomer, tautomer or pharmaceutically acceptable salt, as a selective inhibitor of FGFR4 kinase and its application in the preparation of drugs or pharmaceutical compositions for the treatment of diseases caused by FGFR4 or Fgf19. The compound disclosed in the invention has a selective and significant inhibitory activity on FGFR4 and has a wide range of applications in the field of tumor therapy Jing.
【技术实现步骤摘要】
【国外来华专利技术】PCT国内申请,说明书已公开。
【技术保护点】
PCT国内申请,权利要求书已公开。/n
【技术特征摘要】
【国外来华专利技术】20170102...
【专利技术属性】
技术研发人员:刘建余,张海东,
申请(专利权)人:上海喆邺生物科技有限公司,
类型:发明
国别省市:上海;31
还没有人留言评论。发表了对其他浏览者有用的留言会获得科技券。